Lv32
380 积分 2023-01-12 加入
Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD)
1小时前
待确认
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
2小时前
已完结
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
4小时前
已完结
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
4小时前
已完结
The impact of insulin resistance on the kidney and vasculature
1天前
已完结
Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study
1个月前
已完结
Pharmacokinetics of Icosapent Ethyl: An Open‐Label, Multiple Oral Dose, Parallel Design Study in Healthy Chinese Subjects
1个月前
已完结
Early investigational drugs targeting PPAR-α for the treatment of metabolic disease
1个月前
已完结
Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study
1个月前
已完结
Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives
1个月前
已完结
皖公网安备34019202002308
